Retrospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Mar 21, 2019; 25(11): 1398-1408
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1398
Table 1 Baseline demographics of the 207 patients
CharacteristicsValue
Gender (male, %)118 (57%)
Age of HBeAg seroconversion (yr)40 (34-45)1
Follow-up duration (yr)13.1 (11.8-15.5)1
Liver biochemistry
Bilirubin (μmoL/L)12 (9-16)1
ALP (U/L)69 (57-82)1
AST (U/L)29 (23-37)1
ALT (U/L)32 (21-50)1
GGT (U/L)23 (16-36)1
Albumin (g/dL)43 (41-45)1
Globulin34 (31-36)1
AFP (ng/mL)4 (3-7)1
HBV DNA (log IU/mL)4 (3-5.4)1
Baseline M2BPGi0.42 (0.27-0.68)1
Table 2 Factors associated with development of hepatocellular carcinoma in 207 treatment-naïve chronic hepatitis B patients
Univariate analysis
Multivariate analysis
HCC (n = 14)No HCC (n = 193)P valueOR95%CIP value
Gender (being male, %)10 (71.4%)108 (56%)0.403
Age of HBeAg seroconversion (yr)5339< 0.0011.1961.034-1.3820.016
Bilirubin (μmoL/L)11100.797
ALP (U/L)74580.177
AST (U/L)44240.0021.0420.906-1.1990.564
ALT (U/L)61270.0071.0300.969-1.0940.347
GGT (U/L)59220.0030.9810.932-1.0330.471
Albumin (g/L)43440.427
Globulin36340.157
AFP (ng/mL)430.587
HBV DNA (log IU/mL)4.64.00.446
Baseline M2BPGi (COI)1.390.38< 0.0014.6661.296-16.8020.018
5-year M2BPGi (COI)1.450.47< 0.001
10-year M2BPGi (COI)1.20.550.001
5-year LS (kPa)12.66.40.028
Cirrhosis (%)13 (92.8%)22 (11.4%)< 0.0017.1420.270-188.6930.239
Treatment after HBeAg seroconversion10 (71.4%)92 (47.7%)0.102
HBsAg seroclearance (%)0 (0%)7 (3.6%)0.608